296 related articles for article (PubMed ID: 24462521)
1. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Győrffy B; Bottai G; Lehmann-Che J; Kéri G; Orfi L; Iwamoto T; Desmedt C; Bianchini G; Turner NC; de Thè H; André F; Sotiriou C; Hortobagyi GN; Di Leo A; Pusztai L; Santarpia L
Mol Oncol; 2014 May; 8(3):508-19. PubMed ID: 24462521
[TBL] [Abstract][Full Text] [Related]
2. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
[TBL] [Abstract][Full Text] [Related]
3. Preferential killing of p53-deficient cancer cells by reversine.
Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
[TBL] [Abstract][Full Text] [Related]
4. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
5. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
7. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
9. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
Faisal A; Mak GWY; Gurden MD; Xavier CPR; Anderhub SJ; Innocenti P; Westwood IM; Naud S; Hayes A; Box G; Valenti MR; De Haven Brandon AK; O'Fee L; Schmitt J; Woodward HL; Burke R; vanMontfort RLM; Blagg J; Raynaud FI; Eccles SA; Hoelder S; Linardopoulos S
Br J Cancer; 2017 Apr; 116(9):1166-1176. PubMed ID: 28334731
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
[TBL] [Abstract][Full Text] [Related]
12. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
14. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
15. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
16. Ablation of the spindle assembly checkpoint by a compound targeting Mps1.
Schmidt M; Budirahardja Y; Klompmaker R; Medema RH
EMBO Rep; 2005 Sep; 6(9):866-72. PubMed ID: 16113653
[TBL] [Abstract][Full Text] [Related]
17. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
18. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
Maia ARR; Linder S; Song JY; Vaarting C; Boon U; Pritchard CEJ; Velds A; Huijbers IJ; van Tellingen O; Jonkers J; Medema RH
Br J Cancer; 2018 Jun; 118(12):1586-1595. PubMed ID: 29736010
[TBL] [Abstract][Full Text] [Related]
19. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.
Tannous BA; Kerami M; Van der Stoop PM; Kwiatkowski N; Wang J; Zhou W; Kessler AF; Lewandrowski G; Hiddingh L; Sol N; Lagerweij T; Wedekind L; Niers JM; Barazas M; Nilsson RJ; Geerts D; De Witt Hamer PC; Hagemann C; Vandertop WP; Van Tellingen O; Noske DP; Gray NS; Würdinger T
J Natl Cancer Inst; 2013 Sep; 105(17):1322-31. PubMed ID: 23940287
[TBL] [Abstract][Full Text] [Related]
20. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
